21 GRANT INCOME
|
€ in thousands |
Amount granted |
Received at December 31, |
Still to receive at December 31, |
Recognised as grant income for the years ended December 31, |
||||||||||||||||||||||||||||||||||||
| 2017 | 2016 | 2015 | 2017 | 2016 | 2015 | 2017 | 2016 | 2015 | ||||||||||||||||||||||||||||||||
|
IWT 18 |
886 | 886 | 886 | 708 | 0 | 0 | 178 | 0 | 178 | 0 | ||||||||||||||||||||||||||||||
|
IWT 19 |
1,113 | 1,113 | 1,674 | 1,116 | 0 | 420 | 978 | (76 | ) | 120 | 484 | |||||||||||||||||||||||||||||
|
IWT 20 |
445 | 445 | 356 | 267 | 0 | 89 | 178 | 89 | 89 | 75 | ||||||||||||||||||||||||||||||
|
IWT 21 |
243 | 243 | 368 | 276 | 0 | 92 | 184 | (44 | ) | 27 | 220 | |||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Total |
2,687 | 2,687 | 3,284 | 2,367 | 0 | 601 | 1,518 | (31 | ) | 414 | 779 | |||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
The Company received several grants to support various research programs from an agency of the Flemish government to support technological innovation in Flanders (‘IWT’ – Agency for Innovation and Entrepreneurship). These grants carry clauses which require the Company to maintain a presence in the Flemish region for a number of years and invest according to pre-agreed budgets. The amounts still to receive mentioned in the table above are not recognized as receivables in the statement of financial position as there are conditions attached which are not yet met.
The Company received a fixed percentage of the expenses incurred in the following research and development projects:
IWT 18: T-cell recruiting Nanobodies for targeted delivery
|
Grantor: |
IWT | |||
|
Start date: |
June 1, 2013 | |||
|
End date: |
May 31, 2015 | |||
|
Amount granted: |
€ | 885,597 | ||
|
Amount recognized: |
€ | 885,597 | ||
|
Amount received: |
€ | 885,597 |
IWT 19: Development of a novel Nanobody-based therapeutic platform for treatment of ocular diseases
|
Grantor: |
IWT | |||
|
Start date: |
April 1, 2014 | |||
|
End date: |
March 31, 2017 | |||
|
Amount granted: |
€ | 1,112,926 | ||
|
Amount recognized: |
€ | 1,112,926 | ||
|
Amount received: |
€ | 1,112,926 |
IWT 20: Bispecific Nanobodies with enhanced specificity
|
Grantor: |
IWT | |||
|
Start date: |
June 1, 2014 | |||
|
End date: |
May 31, 2016 | |||
|
Amount granted: |
€ | 445,027 | ||
|
Amount recognized: |
€ | 445,027 | ||
|
Amount received: |
€ | 445,027 |
IWT 21: Development of Nanobody-based immunotoxins
|
Grantor: |
IWT | |||
|
Start date: |
June 1, 2014 | |||
|
End date: |
May 31, 2016 | |||
|
Amount granted: |
€ | 243,489 | ||
|
Amount recognized: |
€ | 243,489 | ||
|
Amount received: |
€ | 243,489 |